Speaker 1: Bloomberg Audio Studios, podcasts, radio News.
Speaker 2: The Stock Movers Report, your roundup of companies making moves
Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
Speaker 3: Now, let's look at some of the stocks on the
Speaker 3: move today in Europe. I'm Caroline Hepgett and I'm joined
Speaker 3: by Bloomberg reporter Louise Moon. Louise, good to have you
Speaker 3: with me. Nova Nordisk surging today, investors salivated because there's
Speaker 3: been a new step forward for this drug maker.
Speaker 1: Yeah, a real crucial step actually. So they've won approval
Speaker 1: in the US to sell a pill version of wei Goovy,
Speaker 1: their their blockbuster OBC drug. So that should start from
Speaker 1: January and it's at a starting price of one hundred and
Speaker 1: forty nine dollars a month. But the reason it's crucial
Speaker 1: is Nova essentially kind of created this whole market and
Speaker 1: then they've been struggling to keep up, particularly in competition
Speaker 1: with the US rival Eli Lilly. And if you look
Speaker 1: at their both to their share prices over the past
Speaker 1: year or so, you can see a real divergence. So
Speaker 1: Eli Lilly kind of shooting quite far higher, and Novo
Speaker 1: has has had quite big losses really really this year,
Speaker 1: so they're trying to keep up, they're trying to stay
Speaker 1: competitive and have having lost ground to Eli Lilly, so
Speaker 1: they're kind of relying on this new pill to fuel
Speaker 1: that growth. So, as I say, so that will start
Speaker 1: in January in the US, and they've also filed for
Speaker 1: approval in Europe and elsewhere, so if and when that comes,
Speaker 1: that could see it expanding out more globally. So as
Speaker 1: you say, I mean, as you mentioned before, the stocks
Speaker 1: is a lot higher on this news this morning, so
Speaker 1: a bit of a boost to them. And then on
Speaker 1: Eli Lilly's side, they've said that their own version could
Speaker 1: be approved in March, so then it will kind of
Speaker 1: remain to be seen how that then plays out between
Speaker 1: the two in terms of competition.
Speaker 3: Yeah, never know. This share price up six point six
Speaker 3: percent at lease this morning, couldn't help. But notice that
Speaker 3: the pill version apparently people drop about sixteen percent of
Speaker 3: their body I was a standard by that, Yeah, which
Speaker 3: is I think less than the JAB, But it means
Speaker 3: that you can take the pill on a more sort
Speaker 3: of ongoing basis. So I think that is the argument,
Speaker 3: and obviously it's easier to do than I guess an injection,
Speaker 3: so that on never nor disc are a huge bearmouth
Speaker 3: of a business for Europe. Of course, now trouble at
Speaker 3: the farm or Staid's wind.
Speaker 1: Farm, that is, yes, So this is the latest of
Speaker 1: the Trump administration. There's been a tumultuous year between the
Speaker 1: Trump administration and the clean energy sector. And this was
Speaker 1: news yesterday's it's a bit of a day to but
Speaker 1: the austed stock is continuing to react. So the US
Speaker 1: has suspended leases for all five wind farms that are
Speaker 1: under construction off the east coast of America, and Bloomberg
Speaker 1: estimates put the total committed capital for those five wind
Speaker 1: farms at about twenty eight billion your stolets, So it's.
Speaker 3: Big, a big deal.
Speaker 1: This was so this was as I say, it was announced
Speaker 1: yesterday and their citing national national security concern and so
Speaker 1: they're saying that the turbines could get in the way
Speaker 1: of radar systems. So, as I say, the industry has
Speaker 1: been kind of repeatedly targeted by the Trump administration. If
Speaker 1: you look at or sid's share price in particular, it's
Speaker 1: it's been kind of up and down, slumping quite heavily
Speaker 1: on some of this news throughout the year. Yesterday it
Speaker 1: was really hit by this, and then today slightly down
Speaker 1: as well. And then there's also of course another main
Speaker 1: one in Europe that would be affected as Vestas.
Speaker 3: So yeah, yeah, harmful news, but question marks I think
Speaker 3: also about whether legally that will hold up, that idea
Speaker 3: of the national security will exactly shoe.
Speaker 1: Yeah, And there was a note also just to say
Speaker 1: from Jeffreys saying that they kind of would expect in
Speaker 1: the long run needs to actually go through. So as
Speaker 1: you say, that's kind of ties into that legality point. Okay,
Speaker 1: Pets at Home have a new top dog. I've been
Speaker 1: galing everyone on the team because we have a new
Speaker 1: pet at Home, but not a dog, it's a cat anyway,
Speaker 1: Pets at Home tell me more. Yes, a new top dog,
Speaker 1: a new CEO. He's called James Bailey. He comes from Waitros.
Speaker 1: He was managing director at Waitros. So it comes off
Speaker 1: to Pets at Home obviously did very well during COVID
Speaker 1: and then this year particular, have been struggling there in
Speaker 1: the middle of a turnaround. So hoping that the stock
Speaker 1: is rising on this slightly, so I guess there's a
Speaker 1: bit of hopes for renewal in twenty twenty six.
Speaker 2: The Stock Movers Report from Bloomberg Radio. Check back with
Speaker 2: us throughout the day for the latest roundup of companies
Speaker 2: making news on Wall Street and for the latest market
Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
Speaker 2: the Bloomberg Business app.